Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204


Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation

Volume:9   Issue:8
Pp: 888-903
A. Carpi, A. Nicolini, A. Antonelli, P. Ferrari and G. Rossi
DOI: 10.2174/156800909790192392

Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer

Volume:9   Issue:8
Pp: 904-914
J. Bielanska, J. Hernandez-Losa, M. Perez-Verdaguer, T. Moline, R. Somoza, S. Ramon y Cajal, E. Condom, J. C. Ferreres and A. Felipe
DOI: 10.2174/156800909790192400

Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy

Volume:9   Issue:8
Pp: 938-952
X. Liu, R. C. Newton, S. M. Friedman and P. A. Scherle
DOI: 10.2174/156800909790192374

Poly(ADP-ribose) Glycohydrolase Deficiency Sensitizes Mouse ES Cells to DNA Damaging Agents

Volume:9   Issue:8
Pp: 953-962
H. Fujihara, H. Ogino, D. Maeda, H. Shirai, T. Nozaki, N. Kamada, K. Jishage, S. Tanuma, T. Takato, T. Ochiya, T. Sugimura and M. Masutani
DOI: 10.2174/156800909790192419

Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery

Volume:9   Issue:8
Pp: 963-981
A. Ganesan, L. Nolan, S. J. Crabb and G. Packham
DOI: 10.2174/156800909790192428

Antibody-Drug Conjugate Targets

Volume:9   Issue:8
Pp: 982-1004
B. A. Teicher
DOI: 10.2174/156800909790192365